Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term PrEP for MSM with episodic high-risk
NCT02495779Completed
- Start
- Jul 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV). Primary endpoint: Number of Participants With PrEP Adherence at 2 weeks. Started Jul 2015; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02495779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495779.